Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Glaxo, Xenoport's Drug Approved to Treat Shingles Pain


Xenoport's stock is dropping after a big rise this year. The drug Horizant,OK'd last year for restless legs syndrome, is at the center of a legal dispute between the companies.

MINYANVILLE ORIGINAL GlaxoSmithKline (GSK) and biotech company Xenoport (XNPT) won US approval to sell the drug Horizant to patients who have nerve pain caused by shingles. The added use should bolster sales of the drug, which was approved last year to treat a condition known as restless legs syndrome.

Xenoport, which licensed the drug to UK-based Glaxo, says it will receive a $10 million milestone payment from its partner as a result of the approval. The drug is at the center of a dispute between the two companies. In January, Xenport accused Glaxo of not living up to its contractual obligation of maximizing sales of the product and said it planned to terminate the partnership. Glaxo filed a complaint in federal court in Delaware, seeking a judgment. Xenoport then sued Glaxo in California state court accusing the big drug maker of fraud and breach of contract. Xenoport has since said it won't terminate the agreement but the lawsuits continue.

Xenoport received $120 million in total from the Glaxo partnership through the end of March. The biotech reported revenue of $43.5 million last year.

Shares of Xenoport dropped 12% to $5.34 in Thursday morning trading. The stock is still up 40% for the year. Glaxo's US shares rose less than 1% to $44.50 and are down more than 2% this year.

(See Arena Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Onyx Mark Key Dates in June.)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos